Evergreen Capital Management LLC lifted its position in shares of Johnson & Johnson (NYSE: JNJ – Get Rating) by 2.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 122,092 shares of the company stock after buying an additional 3,046 shares during the period. Johnson & Johnson comprises about 0.8% of Evergreen Capital Management LLC’s investment portfolio, making its stock its 20th largest holding. Evergreen Capital Management LLC’s holdings in Johnson & Johnson were worth $ 20,886,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Family CFO Inc acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $ 26,000. Steward Financial Group LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $ 34,000. Iron Horse Wealth Management LLC boosted its position in shares of Johnson & Johnson by 29.9% during the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company stock worth $ 45,000 after buying an additional 61 shares during the period. Gibson Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $ 49,000. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of Johnson & Johnson by 290.7% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company stock worth $ 47,000 after buying an additional 218 shares during the period. 68.78% of the stock is owned by institutional investors.
Several analysts recently issued reports on JNJ shares. The Goldman Sachs Group upped their target price on Johnson & Johnson from $ 163.00 to $ 181.00 and gave the stock a “neutral” rating in a report on Tuesday, April 12th. Citigroup dropped their target price on Johnson & Johnson from $ 210.00 to $ 205.00 in a report on Tuesday, May 17th. Sanford C. Bernstein lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and upped their target price for the stock from $ 180.00 to $ 183.00 in a report on Wednesday, March 16th. Credit Suisse Group upped their target price on Johnson & Johnson from $ 200.00 to $ 205.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Finally, Raymond James upped their target price on Johnson & Johnson from $ 195.00 to $ 196.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $ 190.50.
In other news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $ 173.00, for a total transaction of $ 6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares in the company, valued at $ 12,336,803. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider William Hait sold 29,699 shares of the stock in a transaction that occurred on Thursday, April 21st. The stock was sold at an average price of $ 183.58, for a total value of $ 5,452,142.42. Following the transaction, the insider now owns 80,236 shares in the company, valued at approximately $ 14,729,724.88. The disclosure for this sale can be found here. In the last quarter, insiders have sold 78,161 shares of company stock worth $ 13,895,302. 0.35% of the stock is owned by corporate insiders.
NYSE: JNJ opened at $ 169.46 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. The stock’s 50 day moving average price is $ 178.10 and its two-hundred day moving average price is $ 172.89. The firm has a market capitalization of $ 445.92 billion, a price-to-earnings ratio of 22.84, a P / E / G ratio of 3.35 and a beta of 0.66. Johnson & Johnson has a 12-month low of $ 155.72 and a 12-month high of $ 186.69.
Johnson & Johnson (NYSE: JNJ – Get Rating) last released its quarterly earnings data on Tuesday, April 19th. The company reported $ 2.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $ 2.60 by $ 0.07. The firm had revenue of $ 23.43 billion for the quarter, compared to analyst estimates of $ 23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $ 2.59 earnings per share. Equities research analysts expect that Johnson & Johnson will post 10.23 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were paid a dividend of $ 1.13 per share. The ex-dividend date was Monday, May 23rd. This represents a $ 4.52 dividend on an annualized basis and a dividend yield of 2.67%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $ 1.06. Johnson & Johnson’s dividend payout ratio (DPR) is 60.92%.
About Johnson & Johnson: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE: JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.